Also, the outcomes of patients with AML that we treated with an identical protocol without FLT3 mutations did not change between 2012 and 2020 (data not shown), and the OS improvement of FLT3mut patients was related to a decrease in their relapse risk. This evidence concerns the gene FLT3 and acute myeloid leukemia.